Vall d'Hebron Talks by VHIR 'Molecular Insights into the Pathogenesis of Cerebral Amyloid Angiopathy (CAA): What we can learn from familial Dutch-type CAA'

 Vall d'Hebron Talks by VHIR
  Sala d’actes de la planta 10 de l’Hospital General — See in map
03/10/2023
03/10/2023 -- From 15:00h to 16:00h
Organize :
Vall d'Hebron Institut de Recerca (VHIR)
Modality: Presencial i en línia
Share it:

Speaker: Dr. William E. Van Nostrand, is the Co-Executive Director of the George & Anne Ryan Institute for Neuroscience, Herrmann Professor of Neuroscience, Professor in the Department of Biomedical and Pharmaceutical Sciences at the University of Rhode Island. He has been working in Alzheimer’s disease and related disorders (ADRD) research for more than 30 years and was the first to purify and characterize amyloid precursor protein (APP), the progenitor of amyloid-beta (Ab).  Dr. Van Nostrand’s laboratory investigates pathogenic mechanisms in ADRD with a focus on cerebral amyloid angiopathy and cerebral small vessel disease, aspects of vascular mediated cognitive impairment and dementia (VCID), which are key elements of ADRD. His laboratory also generates and refines rodent models of these disorders as investigational platforms for pathogenesis, biomarker development, and therapeutic testing. 

Cerebral amyloid angiopathy (CAA), is a prevalent cerebral small vessel disease (CSVD), prominent contributor to vascular cognitive impairment and dementia (VCID) in the elderly, and the most common vascular comorbidity in Alzheimer’s disease (AD). CAA is characterized by deposition of amyloid â (Ab) fibrils in cerebral blood vessels leading to cerebral infarction, cerebral micro- and macro-hemorrhages, white matter damage and cognitive decline. In addition to AD and sporadic forms of this condition, several familial forms of CAA exist resulting from mutations that reside within the Ab peptide region of APP gene. The first familial CAA mutation identified in Ab was the Dutch E22Q variant. Dutch-type CAA patients exhibit early-onset primarily larger vessel CAA type-2 with the noticeable absence of parenchymal amyloid plaques commonly found in AD. Dutch-type CAA patients develop recurrent, and often fatal, intracerebral hemorrhages and cognitive impairment. Modeling familial Dutch-type CAA provides the opportunity to understand how this mutation drives the specific formation of vascular amyloid and the vascular-associated pathology characteristic of CAA. The objectives of this presentation are two-fold: First, to present new structural and functional studies as to how the Dutch E22Q mutation, and other CAA-related mutations, affect the properties of the Ab peptide to promote fibril assembly. Second, to present studies on the generation of a transgenic rat model of Dutch-type CAA that provide new insights into the molecular pathogenesis of this disease. 

Host: Dr. Mar Hernández Guillamón; Main researcher Neurovascular Diseases (VHIR)

Registre Online: https://gencat.zoom.us/webinar/register/WN_xhqiZHOLQlSrmIQhJkFIgA

 

Related activities

IV Split Liver Transplantation Course: Theoretical and Practical Aspects

03/06/2024 - 09:00
More information

Actualización en el diagnóstico y tratamiento de las enfermedades digestivas

03/07/2024 - 09:00
More information

Preceptorship Hiperoxal·luria primària

Hospital Vall d’Hebron. Edifici General (entrada principal) Planta Baixa Sala 6 de Subdirecció. Pg Vall d'Hebron 119-129. Barcelona
03/14/2024 - 09:00
More information

V360 Simulación en Cirugía Vascular versión 3.0

03/27/2024 - 17:00
Especialistas de Angiología y Cirugía Vascular y residentes en formación con el siguiente perfil: • Médicos en formación en Angiología y Cirugía Vascular de 5º año • Especialista de Angiología y Cirugía Vascular de menos de 10 años de experiencia
More information

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.